IgA Nephropathy

Adult patients with IgAV required dialysis sooner and had shorter survival time compared to patients with IgAN.

Younger age at the time of kidney transplantation, faster progression to end-stage renal disease, a history of kidney transplantation, and no induction therapy were associated with IgAN recurrence, which was linked to poorer graft survival.

Budesonide is the first treatment to receive approval from the FDA for reducing the loss of kidney function in adults with primary IgAN.

The 3-year and 5-year renal survival rates did not exhibit significant changes, but IgAN's 10-year renal survival has shown gradual decreases since the 1990s.

In the new study, 71% of the patients who developed gross hematuria after a COVID-19 vaccination were females, and for 92% of the patients, the investigators observed gross hematuria had developed after the second or subsequent vaccinations.

New data shows one-quarter of patients with kidney disease associated with IBD progress to end-stage disease, with primary determinants including age and baseline eGFR.

Investigators reported that AI programs such as LightGBM could potentially significantly benefit the diagnosis of Berger disease.

Advanced kidney disease, type 2 diabetes, and high risk of disease progression were prevalent among the cohort based on records collected from the HealthVerity database.

Part 1 of the study evaluates reduction in urine protein: creatinine ratio, and part 2 of the study evaluates the number of patients achieving complete remission when on the bruton tyrosine kinase inhibitor for primary membranous nephropathy.

Results highlighted an association between socioeconomic deprivation and greater risk of progression to kidney failure in patients with IgAN.

The ravulizumab group had a proteinuria reduction of 40.3% while the placebo group had a reduction of 10.9% by week 26, highlighting ravulizumab’s effectiveness in treating patients with IgA Nephropathy.

Joanthan Barratt, MD, discusses the results of a RaDaR analysis aimed at examining trends in time-averaged proteinuria and eGFR slope in patients with IgA nephropathy.

Data for a pair of studies presented at Kidney Week 2023 provide an overview of the effects of eGFR and how this might translate to potential long-term benefit in patients IgA nephropathy.

Data from multiple presentations at ASN Kidney Week 2023 offer insight into the effects of atacicept in patients with IgA nephropathy as well as the design of the phase 3 trial, which is currently enrolling.

Preliminary data from the open-label RUBY-3 trial were presented at the American Society of Nephrology Kidney Week 2023.

The 2-year data from the PROTECT study confirms the sustained benefit of sparsentan in patients with IgA nephropathy.

Presented at ASN Kidney Week 2023, results of the ENVISION trial provide the latest insight into effects of sibeprenlimab in management of IgA nephropathy as the nephrology community awaits the results of its ongoing phase 3 trial.

Atrasentan demonstrated superiority versus placebo for reduction in proteinuria through 36 weeks.

Patients with IgA nephropathy experienced nearly 30% proteinuria reduction after 6 months of treatment with SGLT2 inhibitors.

Findings showed the probability of achieving total remission was significantly greater in the corticosteroid pulse group compared to the oral corticosteroid group.

Interim results from the phase 3 APPLAUSE-IgAN study showed a statistically significant reduction in proteinuria among patients treated with iptacopan compared to placebo.

Positive findings from NefIgArd demonstrated budesonide’s ability to modulate the intestinal immune network responsible for IgA production.

Phase 3 data show a significant clinical profile associated with durable reductions in IgA nephropathy biomarkers among patients treated with Nefecon.

Discussing the key differences in the results of ISCHEMIA and ISCHEMIA-CKD, which examined whether the use of invasive or conservative strategies was more effective for patients with ischemic heart disease.

Topline data from Rigel Pharmaceuticals’ proof-of-concept Phase 2 study of fostamatinib in patients with IgA nephropathy, or Berger’s disease, were announced today.